Abstract: Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: Compositions and methods for the detection and treatment of ADHD are provided.

Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis are disclosed.

Abstract: Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.

Abstract: This application relates to methods of diagnosing and treating anorexia nervosa (AN) and binge eating disorder (BED) with a nonselective activator of metabotropic glutamate receptors (mGluRs).

Abstract: Compositions and methods for the detection and treatment of ADHD are provided.

Abstract: Compositions and methods for the detection and treatment of obesity and other neurological disorders are provided.

Abstract: Compositions and methods for the detection and treatment of schizophrenia are provided.

Abstract: This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes.

Abstract: This disclosure relates to the identification of a subset of mGluR network gene CNVs that are predictive of efficacy of treatment with fasoracetam, as well as the identification of an mGluR network gene CNV that is predictive of an increased likelihood of having ADHD as well as having certain symptoms associated with ADHD.

Abstract: Compositions and methods for the detection and treatment of ADHD are provided.

Abstract: Compositions and methods for the diagnosis and treatment of lymphatic anomaly are disclosed.

Abstract: Compositions and methods useful for the diagnosis and treatment of juvenile idiopathic arthritis are disclosed.

Abstract: Compositions and Methods for the Treatment of Amyloid Deposit diseases, e.g., Hereditary cystatin C amyloid angiopathy and other neurodegenerative disorders, are disclosed.

Abstract: Compositions and methods for the diagnosis and treatment of POTS are disclosed. In one aspect, a method for identifying a human subject having a predisposition for, or having, postural orthostatic tachycardia syndrome (POTS) is provided. An exemplary embodiment comprises obtaining a nucleic acid sample from said subject; detecting a nucleic acid having one or more single nucleotide polymorphisms (SNPs) in the locus encoding PPP1R12B selected from rs12741415 and/or GSA-rs116062217, or a SNP in linkage disequilibrium with one or more of the SNPs, by contacting the nucleic acid sample with a probe or primer of sufficient length and composition to detect the SNP; and identifying the subject as having a predisposition for POTS if one or more SNPs are identified.

Abstract: Compositions and methods for the treatment of CLEC16A associated disorders are disclosed.

Abstract: Compositions for the diagnosis and treatment of asthma are disclosed. In accordance with the present invention, a method for detecting, diagnosing and/or treating asthma in a human subject of African descent is provided. An exemplary method comprises detecting at least one single nucleotide polymorphism (SNP) listed in Table I or a SNP in linkage disequilibrium with one or more of the SNPs selected from rs2529168, rs2529136, rs2429063, rs2529155, 7:21303293, rs2700292, rs2700296, 7:21328865, rs10267234, and rs150512506 or a SNP in LD with any of said SNPs, in a nucleic acid sample from the subject, wherein detection is correlated with an increased risk, susceptibility, or predisposition to asthma.

Abstract: Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment is with nonspecific activators of mGluRs such as fasoracetam.